May 1, 2017
Horizon Pharma plc Announces FDA Approval to Expand the Age Range for RAVICTI® to People with Urea Cycle Disorders Ages Two Months +
Read More
September 17, 2015
Rare Disease Reports: FDA Accepts Sarepta’s Sarepta’s NDA for Eteplirsen. PDUFA Date Set
Read More
May 7, 2015
CureDuchenne Celebrates Submission of First-Ever New Drug Application for Duchenne Muscular Dystrophy
Read More
X